SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced the presentation today of positive data from a preclinical study with APOPTONE™ (HE3235), its lead investigational drug candidate for cancer. In this study APOPTONE inhibited the growth of androgen-independent human tumors LuCaP 35V grown subcutaneously as well as growth of C4-2B cells in the bone environment of castrated mice. The results were presented today by Dr. Eva Corey from the University of Washington, who conducted the study, at the 2008 American Association of Cancer Research meeting being held in San Diego, California. The Company also announced it has received regulatory clearance to commence a Phase I/II dose ranging clinical trial with APOPTONE in prostate cancer patients. The patient population for this initial clinical trial will be considered “late stage,” which is defined as patients failing at least one round of chemotherapy.
